As part of its Between the Lines™ video series, CancerNetwork® spoke with Liliana Bustamante, MD, hematologist and medical oncologist at Florida Cancer Specialists in Fort Myers, Florida and Richard Kim, MD, service chief of Medical Gastrointestinal Oncology and senior member in the Gastrointestinal Oncology Department at the Moffitt Cancer Center in Tampa, Florida, about the prognostic potential of circulating tumor DNA (ctDNA) as a biomarker for patients with oligometastatic colorectal cancer.

In the video series, Bustamante and Kim discussed the following:

·      Presentation: ctDNA Assays For Patients With CRC Undergoing Resection of Metastases

·      Key Takeaways: ctDNA Assays For Patients With CRC Undergoing Resection of Metastases

·      ctDNA as a Biomarker in CRC

·      ctDNA Assays in CRC: Interpreting Clinical Findings

·      ctDNA Assays in CRC: Impact on Clinical Practice

·      Next Steps in Using ctDNA as a Biomarker in CRC

·      Recap: Prognostic Potential of ctDNA for Oligometastatic Colorectal Cancer

To watch more videos in CancerNetwork®’s Between the Lines™ series, visit cancernetwork.com/between-the-lines.

Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify or anywhere podcasts are available.